Vascular Biology in Clinical Practice © Vol. 6, No. 1
• How low should LDL-C level be? New data, new direction
This monograph, How low should LDL-C level be? New data, new direction,
offered as part of a series of continuing medical education activities from the University of Florida College of Medicine. Co-editors are Carl J. Pepine, MD, University of Florida College of Medicine, and Robert A. Vogel, MD, University of Maryland School of Medicine.
This monograph examines the issue of how low the level of low-density lipoprotein cholesterol (LDL-C) should be to achieve the greatest health benefit. Data are presented from important, recent clinical studies of LDL-C-lowering therapy in high-risk patients, which demonstrate the power of aggressive lipid lowering to minimize coronary heart disease events and halt the progression of atherosclerosis. Evidence from these studies is strong support for the hypothesis that when it comes to LDL-C, lower is better, and that risk, rather than LDL-C level, should be the main determinant for drug therapy. As a result, the National Cholesterol Education Program Adult Treatment Panel III (ATP III) recently updated clinical practice guidelines for cholesterol management, and advises physicians to consider more intensive treatment options for high-risk patients. The monograph includes highlights of the updated ATP III recommendations. For now, the physiologically normal level of LDL-C continues to be debated--but as new evidence emerges, therapeutic goals may be revised, once again.
The editorial contents of this monograph express the views of the individual contributors and do not necessarily reflect the views or recommendations of the University of Florida College of Medicine, University of Maryland School of Medicine, or the publisher. The reader is advised to consult the full prescribing information for all medications prior to use.
Supported by an unrestricted educational grant from Pfizer Inc.
© 2004 MEDCONSM All rights reserved.